Citius Pharmaceuticals CTXRW 深 沪
等待开盘 08-23 09:30:00 美东时间
0.1441
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.1441
- 总市值 1941.04万
- 52周最高 1.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.012
- 委 比 0.00%
- 总股本 1.35亿
- 历史最高 2.89
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.012
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Citius Oncology Deploys AI Platform To Bolster Commercial Strategy Ahead Of LYMPHIR Launch
Proprietary model informs targeted sales and marketing strategies with feedback loop thataugments precision and impact of targeting and engagementCRANFORD, N.J., Aug. 22, 2025 /PRNewswire/ -- Citius Oncology, Inc.
08-22 20:49
D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $6 Price Target
D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $6 price target.
08-14 00:16
Citius Oncology Announces Pricing of $9.0 Million Public Offering
CRANFORD, N.J., July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: ...
07-16 21:15
Cencora distribution deal boosts Citius shares
Citius Pharmaceuticals (NASDAQ:CTXR) traded higher in the premarket on Tuesday after the company announced that its majority-owned subsidiary, Citius Oncology (NASDAQ:CTOR), reached a distribution ser...
07-15 20:56
Citius Oncology Partners With Cencora To Boost Commercial Launch And Distribution Of FDA-Approved Immunotherapy LYMPHIR
Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™CRANFORD, N.J., July 15, 2025 /PRNewswire/ --
07-15 20:35
Citius Pharmaceuticals regains Nasdaq compliance
Citius Pharmaceuticals (NASDAQ:CTXR) announced on Tuesday it received a Nasdaq notification, indicating that the company regained compliance with Nasdaq's minimum bid price requirement rule of $1.00 p...
07-08 20:48
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
CRANFORD, N.J. , July 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) today announced that it has received formal notification from Th...
07-08 20:34
D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $6 Price Target
D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $6 price target.
06-30 19:24
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
CRANFORD, N.J., June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nas...
06-17 20:08
Citius Pharmaceuticals Closes $6M Securities Offering
An update from Citius Pharmaceuticals ( ($CTXR) ) is now available. On June 9, ...
06-12 21:17
